Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Boosted by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 13.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,292 shares of the medical research company’s stock after acquiring an additional 153 shares during the period. Elevated Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $686,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock valued at $16,582,503,000 after acquiring an additional 180,618 shares in the last quarter. State Street Corp grew its holdings in shares of Thermo Fisher Scientific by 0.3% during the 2nd quarter. State Street Corp now owns 16,116,956 shares of the medical research company’s stock valued at $8,414,693,000 after acquiring an additional 55,458 shares in the last quarter. Morgan Stanley boosted its holdings in Thermo Fisher Scientific by 0.4% in the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after purchasing an additional 50,736 shares in the last quarter. Moneta Group Investment Advisors LLC boosted its holdings in Thermo Fisher Scientific by 104,536.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after purchasing an additional 8,347,260 shares in the last quarter. Finally, Capital Research Global Investors boosted its holdings in Thermo Fisher Scientific by 2.7% in the second quarter. Capital Research Global Investors now owns 6,091,325 shares of the medical research company’s stock worth $3,178,095,000 after purchasing an additional 157,512 shares in the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

TMO opened at $584.15 on Friday. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The company’s 50 day simple moving average is $559.33 and its 200-day simple moving average is $518.31. The stock has a market capitalization of $222.74 billion, a P/E ratio of 37.81, a price-to-earnings-growth ratio of 2.49 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same period last year, the firm earned $5.40 earnings per share. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last ninety days. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent research reports. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. HSBC initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, December 18th. They issued a “buy” rating and a $610.00 price objective for the company. Citigroup upped their price target on shares of Thermo Fisher Scientific from $530.00 to $575.00 and gave the company a “buy” rating in a report on Monday, December 11th. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $596.00.

Read Our Latest Stock Analysis on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.